A randomized, double-blind, placebo controlled, two-treatment and two-period cross-over, mono-center study to evaluate the efficacy and safety of daglutril 300mg once daily compared to placebo on top of losartan in type 2 diabetics with overt nephropathy and well controlled hypertension.
Phase of Trial: Phase II
Latest Information Update: 27 Apr 2010
At a glance
- Drugs Daglutril (Primary)
- Indications Diabetic nephropathies; Hypertension; Proteinuria
- Focus Therapeutic Use
- 13 Nov 2007 Status changed from recruiting to completed.
- 18 Dec 2005 New trial record.